Seskind Coleman R MD is categorized under Internal Medicine Doctors in Chicago, IL and active since 1968.
Seskind Coleman R MD was established in 1968, and today employs 1 to 4, earning $500.000 to $999.999 per year. This is a Internal Medicine Doctors business, which does work in the B2C market, and is classified as a Internal Medicine Doctors, under code number 6211110 by the NAICS.
If you are seeking more information, feel free to contact Coleman Seskind at the company’s single location by writing to 333 North Michigan Avenue # 701, Chicago, Illinois IL 60601 or by phoning (312) 726-7595. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Seskind Coleman R MD |
| Contact Person: | Coleman Seskind |
| Address: | 333 North Michigan Avenue # 701, Chicago, Illinois 60601 |
| Phone Number: | (312) 726-7595 |
| Annual Revenue (USD): | $500.000 to $999.999 |
| Founded: | 1968 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2C (Business to Consumer) |
| Business Category: | Internal Medicine Doctors |
| SIC Code: | 8011 |
| NAICS Code: | 6211110 |
| Share This Business: |
Seskind Coleman R MD was started in 1968 to provide professional Internal Medicine Doctors under the SIC code 8011 and NAICS code 6211110. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $500.000 to $999.999 per annum.
Feel free to contact Coleman Seskind for inquiries that concern Seskind Coleman R MD by calling the company number (312) 726-7595, as your correspondence is most welcome. Additionally, the physical location of the single location of Seskind Coleman R MD can be found at the coordinates 41.887695,-87.624479 as well as the street address 333 North Michigan Avenue # 701 in Chicago, Illinois 60601.
For its online presence, you may visit Seskind Coleman R MD’s website at and engage with its social media outlets through on Twitter and on Facebook.